|
MechanismTop II inhibitors |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multi-center, Randomized, Controlled, Open-label Phase II/III Clinical Trial to Investigate Whether Transarterial Tirapazamine Injection Followed by Transarterial Embolization (TATE) is Superior to Traditional Transarterial Chemoembolization (TACE) in Patients With Intermediate-Stage Hepatocellular Carcinoma (HCC)
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.
Phase IIA Clinical Trial of Intra-arterial Administration of Tirapazamine Followed by Transarterial Embolization (TATE)and KN046 for the Treatment of Advanced Colorectal Cancer with Liver Metastasis (MSS/pMMR)
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.
经肝动脉注射替拉扎明再行肝动脉栓塞(TATE)与KN046联合治疗晚期肝转移性结直肠癌(MSS/ pMMR)的IIA期临床试验
[Translation] A phase IIA clinical trial of transarterial tirapazamine followed by hepatic arterial embolization (TATE) combined with KN046 in the treatment of advanced liver metastatic colorectal cancer (MSS/pMMR)
研究经肝动脉注射替拉扎明再行肝动脉栓塞(TATE)与KN046联合治疗晚期肝转移性结直肠癌MSS/pMMR的有效性和安全性
[Translation] To investigate the efficacy and safety of transarterial tirapazamine followed by hepatic arterial embolization (TATE) combined with KN046 in the treatment of advanced liver metastatic colorectal cancer MSS/pMMR
100 Clinical Results associated with Zhejiang Raygene Pharmaceuticals Co., Ltd
0 Patents (Medical) associated with Zhejiang Raygene Pharmaceuticals Co., Ltd
100 Deals associated with Zhejiang Raygene Pharmaceuticals Co., Ltd
100 Translational Medicine associated with Zhejiang Raygene Pharmaceuticals Co., Ltd